{"id":"W2589549609","doi":"10.1200/jco.2005.23.16_suppl.695","title":"Phase I-II study of DalCM-P [daily dalteparin (Dal), cyclophosphamide (C) and prednisone (P) and bi-weekly methotrexate (M)] as therapy for metastatic breast cancer (MBC)","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Metastatic breast cancer; Internal medicine; Chemotherapy; Cyclophosphamide; Gastroenterology; Regimen; Breast cancer; Chemotherapy regimen; Progression-free survival; Phases of clinical research; Cancer; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001826855,0.002570899,0.002345524,0.000793147,0.0005301251,0.000928756,0.001413077,0.001713485,0.005353156],"category_scores_gemma":[0.001292091,0.001106047,0.001067506,0.0005167779,0.001347866,0.001150913,0.0005485736,0.003365707,0.001402596],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001037176,"about_ca_system_score_gemma":0.001873764,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008886817,"about_ca_topic_score_gemma":0.001640602,"domain_scores_codex":[0.9994075,0.0002795803,0.0000245918,0.00009742731,0.00005179075,0.0001390995],"domain_scores_gemma":[0.9988835,0.0001523444,0.0001814733,0.0001097128,0.00005761631,0.0006152496],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7409186,0.166058,0.004464613,0.0004735684,0.0004357091,0.0002580065,0.0002637671,0.00236069,0.03926709,0.0003316129,0.003001251,0.04216716],"study_design_scores_gemma":[0.5356776,0.4520773,0.004990906,0.00001646669,0.0001485882,0.0002131673,0.00004351548,0.0008409088,0.00365076,0.0001999323,0.002117511,0.00002341277],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9861727,0.001232957,0.0009105895,0.0006435632,0.0001630809,0.007583183,0.001301999,0.0001190838,0.001872922],"genre_scores_gemma":[0.9743403,0.001238241,0.003513054,0.00139832,0.0002379028,0.009942734,0.003580321,0.00004158754,0.005707516],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005353156,"threshold_uncertainty_score":0.0179081,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1550670446599501,"score_gpt":0.5456303374866971,"score_spread":0.3905632928267471,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}